Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
TP

NASDAQ · TPST

Tempest Therapeutics, Inc.

Healthcare · Biotechnology

$0.46

Down-$0.01 (-1.13%)

Updated Nov 5, 2026, 2:19 AM

SID Score

2.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.1M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.46 – $5.22
Volume
108.52K
Avg. volume
107.23K

Price performance · TPST

TPST price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

TPST closed at $0.46 after 21 trading sessions, down 41.46% for the selected period.

Last close
$0.46
Period change
-41.46%
Period low
$0.46
Period high
$0.79
Daily close
View OHLC price history
TPST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.462$0.4997$0.4552$0.4633108.52K
Nov 3, 2026$0.4965$0.4999$0.4638$0.4686140.98K
Nov 2, 2026$0.50$0.507$0.4701$0.472160.45K
Oct 30, 2026$0.5333$0.5466$0.4902$0.4955163.47K
Oct 29, 2026$0.549$0.5597$0.53$0.533257.16K
Oct 28, 2026$0.515$0.5399$0.5102$0.5399103.81K
Oct 27, 2026$0.5174$0.5305$0.5105$0.510779.24K
Oct 26, 2026$0.5076$0.5212$0.5005$0.510266.15K
Oct 23, 2026$0.5342$0.542$0.5039$0.51152.25K
Oct 22, 2026$0.5162$0.55$0.5162$0.5223195.96K
Oct 21, 2026$0.57$0.623$0.5202$0.5282372.89K
Oct 20, 2026$0.6004$0.6281$0.573$0.5762144.97K
Oct 19, 2026$0.64$0.64$0.60$0.6001128.47K
Oct 16, 2026$0.668$0.6688$0.6201$0.624267.43K
Oct 15, 2026$0.6327$0.6529$0.6203$0.635122.58K
Oct 14, 2026$0.6964$0.6964$0.635$0.6352180.73K
Oct 13, 2026$0.7465$0.7465$0.6801$0.6813229.93K
Oct 12, 2026$0.7633$0.7775$0.74$0.7427163.61K
Oct 9, 2026$0.7764$0.81$0.76$0.7601182.66K
Oct 8, 2026$0.7864$0.795$0.765$0.77147.7K
Oct 7, 2026$0.79$0.8199$0.75$0.7914308.1K

Latest TPST news

The latest Smart Investors Daily articles mentioning TPST.

Stock researchCompany · Overview

TPST research

Overview

Company profile and research snapshot.

Company profile

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TPST recent ratings
DateFirmRatingTarget
Sep 24, 2026HC Wainwright & Co.Buy—
Jan 22, 2026HC Wainwright & Co.Buy—
Apr 10, 2025ScotiabankSector Perform—
Apr 10, 2025HC Wainwright & Co.Neutral—
Mar 28, 2025ScotiabankSector Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W. Frederick has been appointed to its board of directors. Mr. Frederick brings extensive executive leadership experience spanning financial strategy, capital markets, corporate governance and operational transformatio

Yahoo · Sep 23, 2026

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companiesBRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By